The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
4D pharma plc
(the "Company" or "4D")
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, is pleased to announce that Duncan Peyton (the "Director") has purchased ordinary shares in the Company as listed below. Following this transaction, the Director has a resulting interest in the ordinary shares of the Company as listed below.
Shares in 4D pharma plc before purchase
% of total shares in issue
Shares in 4D pharma plc after purchase
% of total shares in issue
Duncan Peyton (CEO)
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
Details of the person discharging managerial responsibilities / person closely associated
Reason for the notification
Initial notification /Amendment
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
4D Pharma plc
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
Description of the financial instrument, type of instrument
Ordinary shares of £0.0025
Nature of the transaction
Purchase of Ordinary Shares
Price(s) and volume(s)
- Aggregated volume
Date of the transaction
22nd May 2019
Place of the transaction
London Stock Exchange, AIM
For further information please contact:
Duncan Peyton, Chief Executive Officer
Fay Weston, Head of Investor Relations
+ 44 (0)113 895 0130
+ 44 (0)7990 381713
Zeus Capital Limited - Nomad and Joint Broker
+44 (0)161 831 1512
Dan Bate / Jordan Warburton
Bryan Garnier & Co. Limited - Joint Broker
+44 (0)20 7332 2500
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...